The study identifies ALIX-ESCRT-III as a 'secondary pathway' but doesn't explain what cellular conditions or signals dictate pathway choice. This regulatory mechanism could be critical for understanding altered exosome production in neurodegenerative diseases. Gap type: unexplained_observation Source paper: ALIX- and ESCRT-III-dependent sorting of tetraspanins to exosomes. (2020, The Journal of cell biology, PMID:32049272)
Landscape Summary: What determines when cells use the ALIX-ESCRT-III pathway versus the canonical ESCRT pathway for exosome formation? is a 0.75 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What determines when cells use the ALIX-ESCRT-III pathway versus the canonical ESCRT pathway for exosome formation? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: